227 related articles for article (PubMed ID: 24659749)
1. High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.
Tan BX; Khoo KH; Lim TM; Lane DP
Oncotarget; 2014 Feb; 5(4):933-43. PubMed ID: 24659749
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
3. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
4. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract][Full Text] [Related]
5. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.
Li L; Tan Y; Chen X; Xu Z; Yang S; Ren F; Guo H; Wang X; Chen Y; Li G; Wang H
PLoS One; 2014; 9(11):e113088. PubMed ID: 25405759
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
Mol Cancer; 2014 May; 13():116. PubMed ID: 24885082
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
9. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells.
Samudio IJ; Duvvuri S; Clise-Dwyer K; Watt JC; Mak D; Kantarjian H; Yang D; Ruvolo V; Borthakur G
Leuk Lymphoma; 2010 May; 51(5):911-919. PubMed ID: 20423286
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
11. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
[TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M
Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429
[TBL] [Abstract][Full Text] [Related]
13. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
[TBL] [Abstract][Full Text] [Related]
14. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
15. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
16. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
Thompson T; Andreeff M; Studzinski GP; Vassilev LT
Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950
[TBL] [Abstract][Full Text] [Related]
17. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
Voltan R; Secchiero P; Corallini F; Zauli G
Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
[TBL] [Abstract][Full Text] [Related]
18. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
19. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
